Gynecologic cancer: Edited by Anne O. RodriguezClinical aspects of uterine papillary serous carcinomaHamilton, Chad Aa; Kapp, Daniel Sb; Chan, John KcAuthor Information aDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Walter Reed Army Medical Center, Washington, District of Columbia, USA bDepartment of Radiation Oncology, Stanford Cancer Center, Stanford, California, USA cDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California, USA Correspondence to John K. Chan, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, San Francisco, School of Medicine, UCSF Comprehensive Cancer Center, 1600 Divisadero St, Rm A747, Box 1702, San Francisco, CA 94143-1702, USA Tel: +1 415 353 7628; fax: +1 415 885 3586; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology: February 2008 - Volume 20 - Issue 1 - p 26-33 doi: 10.1097/GCO.0b013e3282f2b10d Buy Metrics Abstract Purpose of review We review the demographic and clinicopathologic characteristics, and prognosis of women diagnosed with uterine papillary serous carcinoma, with a focus on clinical management. Recent findings Pathologic evaluation of postmenopausal bleeding is preferred for patients who fit the profile of a high-risk endometrial cancer such as uterine papillary serous carcinoma. Women diagnosed with endometrial cancer who fit this profile and all women with uterine papillary serous carcinoma should undergo comprehensive surgical staging and aggressive cytoreduction of extrauterine disease. Adjuvant therapy remains controversial. Several recent investigations reported on the potential benefit of adjuvant chemotherapy, with many recommending additional loco-regional radiation. Summary Despite the lack of randomized trials on uterine papillary serous carcinoma, several recent reports have provided insight into the diagnosis, surgical management, and adjuvant treatment of this high-risk endometrial cancer. © 2008 Lippincott Williams & Wilkins, Inc.